ArticleAnnals of the rheumatic diseases2007
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.
Article in Annals of the rheumatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 3 syntheses or guidelines pooled it, 338 citations in OpenAlex.
- Combination of Sjögren's syndrome and anti-Ku syndrome complicated by the development of mucosa-associated lymphoid tissue lymphoma: case review and systematic review of the literature.Clinical rheumatology · 2024Pooled it
- A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.Rheumatology (Oxford, England) · 2021Pooled it
- Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis.PloS one · 2014Pooled it
- Cancer-associated myositis: a single-centre 20-year experience.Clinical rheumatology · 2026Article
- Periorbital heliotrope erythema with edema as a potential clinical marker of paraneoplastic Dermatomyositis - a case series.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- Distinct phenotypes and prognosis between Jo-1 and non-Jo-1 subtypes in anti-synthetase syndrome: a retrospective cohort study from China.Clinical rheumatology · 2026Article
- Retrospective analysis of myositis-specific antibody-positive veteran survival between 2011 and 2023.Clinical rheumatology · 2026Article
- Malignancy in Idiopathic Inflammatory Myopathies: Recent Insights.Clinical reviews in allergy & immunology · 2025Review
- Article
- Microvascular abnormalities between anti-TIF1-γ-associated dermatomyositis with and without malignancy.BMC rheumatology · 2025Article
- An update on autoantibodies in the idiopathic inflammatory myopathies.Nature reviews. Rheumatology · 2025Review
- Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives.Frontiers in oncology · 2025Review
- Long-Term Dysphagia Severity in Patients With Idiopathic Inflammatory Myopathy: A Single-Center Retrospective Study.Cureus · 2024Article
- Paraneoplastic Cerebellar Degeneration Associated with Breast Cancer: A Case Report and a Narrative Review.Brain sciences · 2024Review
- Advances of autoimmune rheumatic diseases related to malignant tumors.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Review
- Diagnostic Yield of Computed Tomography for Cancer Detection in a Tertiary Referral Population of Idiopathic Inflammatory Myositis Patients.Arthritis care & research · 2023Article
- Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series.Rheumatology (Oxford, England) · 2023Article
- [Dermatomyositis and juvenile dermatomyositis].Zeitschrift fur Rheumatologie · 2023Review
- Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.Clinical rheumatology · 2023Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThere is a known association between myositis and cancer. The risk is greater in dermatomyositis (DM) than polymyositis (PM), although reliable methods to predict cancer risk in specific patients with myositis are not presently available. This study was undertaken to determine whether risk of developing cancer in myositis can be predicted by antibody profiling.
methodsA cross-sectional study of UK Caucasian adults with PM (n = 109), DM (n = 103) and connective tissue disease overlap (myositis/CTD-overlap, n = 70). Patients were tested for a comprehensive range of myositis-specific/associated autoantibodies. Sensitivity and specificity analyses were performed for the optimal identification of cancer risk.
resultsSixteen patients had cancer-associated myositis (CAM) (15 DM, 1 myositis/CTD-overlap). CAM patients were older at disease onset, and patients without myositis-specific/associated autoantibodies on "routine" laboratory testing (negative for anti-Jo-1, anti-PM-Scl, anti-U1-RNP, anti-U3-RNP, anti-Ku antibodies) had a significantly increased risk of CAM. Possession of the antibody against 155 kDa and 140 kDa protein specificities (anti-155/140 antibody) represented a significant risk factor for CAM, and was found exclusively in DM. A positive anti-155/140 antibody result proved highly specific, moderately sensitive, with high negative predictive value for CAM. A "negative routine myositis antibody panel" result was highly sensitive, with high negative predictive value for CAM. The combination of these two approaches was 94% sensitive, detecting 15 of 16 CAM, with 100% sensitivity and negative predictive value in DM.
conclusionsThese results may help clinicians predict which patients with myositis are at greater risk of developing cancer, thus identifying those requiring aggressive diagnostic evaluation and intensive cancer surveillance at myositis onset and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.